Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
BIIB News
Valued at a market cap of $22.1 billion, Biogen Inc. (BIIB) is a top biotechnology company. Headquartered in Cambridge, Massachusetts, it specializes in the dis...
(RTTNews) - Biogen Inc. (BIIB) and Stoke Therapeutics Inc. (STOK) unveiled new long-term follow-up data from ongoing open-label extension (OLE) studies of zorev...
Biogen (BIIB) and Stoke Therapeutics (STOK) announced the presentation of longer-term follow-up analyses from the ongoing open-label extension studies of zorevu...
Analyst ratings
51%
of 37 ratingsMore BIIB News
If you own Biogen stock, or are thinking about buying in, you might be wondering what to make of all the recent movement in its share price. Over the last month...
(RTTNews) - Eisai Co., Ltd. (ESALY.PK, ESALF.PK, 4523.T) and Biogen Inc. (BIIB) announced the U.S. availability of LEQEMBI IQLIK (lecanemab-irmb) as a subcutane...
Eisai (ESAIY) and Biogen (BIIB) announced that lecanemab-irmb subcutaneous injection, or Leqembi Iqlik, is now available in the U.S. as a maintenance dosing reg...
Biogen (BIIB) just saw Australia’s Therapeutic Goods Administration approve LEQEMBI for early Alzheimer’s in adults. This marks a fresh milestone that expands a...